sCT 9-32

This peptide is an analog of amylin, a hormone co-secreted with insulin by pancreatic beta-cells. Amylin plays a significant role in regulating glucose metabolism and gastric emptying. The analog is designed to mimic the physiological effects of natural amylin, aiming to enhance its stability and efficacy for therapeutic applications.

Applications: The primary application of this peptide analog is in the treatment of metabolic disorders, particularly those related to obesity and binge eating. By modulating appetite and food intake, it serves as a potential therapeutic agent for weight management and the control of eating behaviors.

Biological Importance: Amylin analogs like this peptide are crucial in metabolic research due to their role in appetite regulation and glucose homeostasis. They offer insights into the mechanisms of satiety and have the potential to inform the development of treatments for obesity and related metabolic conditions.

For more detailed information, please refer to the patent document: https://patentimages.storage.googleapis.com/f9/08/6e/bf67884c5529ae/US7879794.pdf

sCT 9-32 is a 24-residue synthetic peptide with the sequence Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro. C-terminal amidation removes the terminal carboxylate charge. The sequence contains 2 Lys and 1 Arg residues, contributing cationic character. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence.

• LC-MS/HPLC analytical method development
• sequence-specific assay controls

Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions.